Financial & competing interests disclosure
Thomas Lehrnbecher has received a grant from Gilead, is a consultant to Astellas, Gilead, Merck, Sharp & Dohme and Schering-Plough, and has served on the speakers’ bureau for Gilead, Merck/MSD, Pfizer and Schering-Plough. Andreas H Groll has received grants from Gilead and Merck, Sharp & Dohme, is a consultant to Astellas, Gilead, Merck, Sharp & Dohme and Schering-Plough, and has served on the speakers’ bureau for Astellas, Gilead, Merck/MSD, Pfizer, Schering-Plough and Zeneus/Cephalon. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.